Tech Company Financing Transactions
Centivax Funding Round
On 11/16/2022, Centivax raised $10 million in Seed funding from Global Health Investment Corporation and NFX.
Transaction Overview
Company Name
Announced On
11/16/2022
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
Global Health Investment Corporation (Lead Investor)
NFX (Lead Investor)
Proceeds Purpose
The company will use the funds to the TechBio Platform Developing Universal Vaccines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Boulevard South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of a therapeutics and clinical-stage company intended to treat and eradicate rapidly mutating pathogens. The company applies its computational immune engineering expertise to develop therapeutic monoclonal antibodies against a variety of targets, it builds a panel of neutralizing antibodies against SARS-CoV-2, enabling people to be safe from health issues with the help of vaccinations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Glanville
Chief Operating Officer
David Tsao
Chief Technical Officer
Nicholas Bayless
Co-Founder
Sawsan Youssef
Browse more venture capital transactions:
Prev: 11/16/2022: Baraka venture capital transaction
Next: 11/16/2022: Pure Electric venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs